Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew P Grigg

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic MelanomaMiles C Andrews, Natalie Turner, Janis Boyd, et al.
Haematologica|August 11, 2011
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease featuresDavid M Ross, Paul A Bartley, Jarrad Goyne, et al.
Thrombosis and Haemostasis|May 13, 2019
Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory ResponseAbdullah Hamadi, Andrew P Grigg, Gasim Dobie, et al.
Cancer|September 17, 2004
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignanciesConstantine S Tam, Max M Wolf, E Henry Januszewicz, et al.
Haematologica|June 1, 2005
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignanciesConstantine Tam, John F Seymour, Michael Brown, et al.
Thrombosis Research|August 6, 2016
The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic stateNaif Alhawiti, Kate L Burbury, Faith A Kwa, et al.
Leukemia & Lymphoma|March 12, 2010
Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphomaAndrew P Grigg, Janey Stone, Alvin D Milner, et al.
Internal Medicine Journal|November 10, 2018
Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasmsCecily J Forsyth, Wai-Hoong Chan, Andrew P Grigg, et al.
Blood|February 8, 2006
More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disordersDavid P Steensma, Animesh Pardanani, William S Stevenson, et al.
Pathology|August 19, 2006
Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral bloodWilliam S Stevenson, Rosemary Hoyt, Anthony Bell, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic MelanomaMiles C Andrews, Natalie Turner, Janis Boyd, et al.
Haematologica|August 11, 2011
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease featuresDavid M Ross, Paul A Bartley, Jarrad Goyne, et al.
Thrombosis and Haemostasis|May 13, 2019
Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory ResponseAbdullah Hamadi, Andrew P Grigg, Gasim Dobie, et al.
Cancer|September 17, 2004
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignanciesConstantine S Tam, Max M Wolf, E Henry Januszewicz, et al.
Haematologica|June 1, 2005
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignanciesConstantine Tam, John F Seymour, Michael Brown, et al.
Thrombosis Research|August 6, 2016
The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic stateNaif Alhawiti, Kate L Burbury, Faith A Kwa, et al.
Leukemia & Lymphoma|March 12, 2010
Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphomaAndrew P Grigg, Janey Stone, Alvin D Milner, et al.
Internal Medicine Journal|November 10, 2018
Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasmsCecily J Forsyth, Wai-Hoong Chan, Andrew P Grigg, et al.
Blood|February 8, 2006
More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disordersDavid P Steensma, Animesh Pardanani, William S Stevenson, et al.
Pathology|August 19, 2006
Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral bloodWilliam S Stevenson, Rosemary Hoyt, Anthony Bell, et al.
Pageof 4